InsiderClue
Stocks · Health care · Pharmaceutical Preparations

ARROWHEAD PHARMACEUTICALS, INC.

ARWR Clue Score51
United States Fiscal year ends September CIK 0000879407 Results filed 4 Aug 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

19
Insider
Date
Role
Action
Shares
Price
Amount
Christopher Richard Anzalone
29 Dec 2025
Chief Executive Officer
Sold after exercise
16,545
$68.69
$1.14M
Christopher Richard Anzalone
29 Dec 2025
Chief Executive Officer
Sold after exercise
35,181
$69.33
$2.44M
Christopher Richard Anzalone
4 Mar 2025
Chief Executive Officer
Sold after exercise
133,333
$17.02
$2.27M
Christopher Richard Anzalone
3 Mar 2025
Chief Executive Officer
Sold after exercise
166,667
$18.03
$3.01M
Christopher Richard Anzalone
31 Jan 2024
Chief Executive Officer
Sold after exercise
19,730
$32.71
$645.37K
Christopher Richard Anzalone
31 Jan 2024
Chief Executive Officer
Sold after exercise
37,769
$32.16
$1.21M
Christopher Richard Anzalone
18 Sep 2023
Chief Executive Officer
Sold after exercise
26,232
$28.27
$741.58K
Christopher Richard Anzalone
18 Sep 2023
Chief Executive Officer
Sold after exercise
31,523
$28.00
$882.64K
Christopher Richard Anzalone
4 May 2023
Chief Executive Officer
Sold after exercise
25,992
$40.02
$1.04M
Christopher Richard Anzalone
4 May 2023
Chief Executive Officer
Sold after exercise
24,008
$38.97
$935.59K
Christopher Richard Anzalone
3 May 2023
Chief Executive Officer
Sold after exercise
54,928
$39.14
$2.15M
Christopher Richard Anzalone
11 Feb 2022
Chief Executive Officer
Sold after exercise
1,900
$50.51
$95.97K
Christopher Richard Anzalone
11 Feb 2022
Chief Executive Officer
Sold after exercise
61,482
$50.90
$3.13M
Christopher Richard Anzalone
11 Feb 2022
Chief Executive Officer
Sold after exercise
42,153
$52.28
$2.20M
Christopher Richard Anzalone
11 Feb 2022
Chief Executive Officer
Sold after exercise
40,853
$53.11
$2.17M
Patrick O'Brien
8 Feb 2021
General Counsel
Sold after exercise
5,436
$89.66
$487.39K
Patrick O'Brien
8 Feb 2021
General Counsel
Sold after exercise
45,348
$88.88
$4.03M
Patrick O'Brien
8 Feb 2021
General Counsel
Sold after exercise
31,255
$88.08
$2.75M
Patrick O'Brien
8 Feb 2021
General Counsel
Sold after exercise
7,961
$86.72
$690.38K
Showing 250 of 427 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 274
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 108
Sales straight out of an exercise 73
Sales at will 209
Transactions with no price 0
Shares from compensation/vesting 12,981,410
Sales filed before the plan box existed 176
History held since 15 Nov 2006